JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.

A large-scale study published in Molecular Psychiatry has uncovered a distinct pattern of biological changes in people with ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other psychedelic ...

Could it be New Zealand’s Largest Class Action? A potential landmark consumer rights case alleges Johnson & Johnson sold New Zealanders decongestants containing a “useless” ingredient for nearly 20 ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Fiancé star Larissa Dos Santos Lima has been diagnosed with major depressive disorder and is stepping away from social media. A rep for the reality star, 38, named Julia Dickson, announced the news on ...

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

Johnson was named the SEC Men's Basketball Freshman of the Week for an astounding fourth time, the team announced. He is coming off a monster week for the (16-10 and 5-8) Longhorns, in which he ...